Propranolol (capsule): Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{Propranolol}} | {{Propranolol}} | ||
{{CMG | {{CMG}} | ||
'''''For patient information, click <u>[[Propranolol (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Propranolol (patient information)|here]]'''''</u>. | ||
{{SB}} Inderal LA<sup>®</sup>, InnoPran XL<sup>®</sup> | {{SB}} Inderal LA<sup>®</sup>, InnoPran XL<sup>®</sup> | ||
Revision as of 21:17, 9 February 2014
| Propranolol |
|---|
| Inderal LA® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Propranolol |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here.
Synonyms / Brand Names: Inderal LA®, InnoPran XL®
Overview
Category
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages